Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-14 4:58 pm Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | Paradigm Biocapital Advisors LP | 2,317,634 5.05% | 102,912 (+4.65%) | View |
| 2023-02-14 4:57 pm Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | GREAT POINT PARTNERS LLC | 3,637,718 7.92% | 189,197 (+5.49%) | View |
| 2023-02-14 4:45 pm Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | RA CAPITAL MANAGEMENT L.P. | 4,397,368 9.6% | 40,736 (+0.94%) | View |
| 2023-02-14 4:05 pm Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | Lynx1 Capital Management LP | 3,126,173 6.8% | 1,588,828 (+103.35%) | View |
| 2023-02-14 3:38 pm Sale | 13G | Alpine Immune Sciences, Inc. ALPN | Avidity Partners Management LP | 1,888,887 4% | -316,800 (-14.36%) | View |
| 2023-02-13 5:57 pm Sale | 13G | Alpine Immune Sciences, Inc. ALPN | BIOTECHNOLOGY VALUE FUND L P | 1,353,815 2.9% | -235,680 (-14.83%) | View |
| 2023-02-13 4:46 pm Unchanged | 13G | Alpine Immune Sciences, Inc. ALPN | Omega Fund VI L.P. | 2,415,050 5.2% | 0 (Unchanged) | View |
| 2022-10-03 5:16 pm Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | Paradigm Biocapital Advisors LP | 2,214,722 5.03% | 2,214,722 (New Position) | View |
| 2022-10-03 4:30 pm Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | RA CAPITAL MANAGEMENT L.P. | 4,356,632 9.91% | 4,356,632 (New Position) | View |
| 2022-09-30 09:37 am Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | GREAT POINT PARTNERS LLC | 3,448,521 7.85% | 3,448,521 (New Position) | View |
| 2022-09-27 5:02 pm Purchase | 13D | Alpine Immune Sciences, Inc. ALPN | Alpine ImmunoSciences L.P. | 3,905,590 8.6% | 237,292 (+6.47%) | View |
| 2022-09-27 4:29 pm Sale | 13D | Alpine Immune Sciences, Inc. ALPN | ORBIMED ADVISORS LLC | 4,081,592 9.3% | -145,251 (-3.44%) | View |
| 2022-09-27 4:00 pm Purchase | 13D | Alpine Immune Sciences, Inc. ALPN | Decheng Capital China Life Sciences USD Fund III L.P. | 7,974,207 17.6% | 2,010,246 (+33.71%) | View |
| 2022-04-22 4:26 pm Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | Lynx1 Capital Management LP | 1,537,345 5.1% | 1,537,345 (New Position) | View |
| 2022-02-15 2:18 pm Sale | 13D | Alpine Immune Sciences, Inc. ALPN | Frazier Life Sciences VIII L.P. | 3,164,108 10.8% | -13,734 (-0.43%) | View |
| 2022-02-14 3:21 pm Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | Omega Fund VI L.P. | 2,415,050 8.2% | 2,415,050 (New Position) | View |
| 2022-02-14 1:15 pm Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | BIOTECHNOLOGY VALUE FUND L P | 1,589,495 5.4% | 451,731 (+39.70%) | View |
| 2022-02-14 11:53 am Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | Decheng Capital Management III (Cayman) LLC | 4,708,288 16.11% | 4,708,288 (New Position) | View |
| 2022-02-11 8:18 pm Purchase | 13G | Alpine Immune Sciences, Inc. ALPN | Avidity Partners Management LP | 2,205,687 7.3% | 735,297 (+50.01%) | View |
| 2021-11-12 5:05 pm Purchase | 13D | Alpine Immune Sciences, Inc. ALPN | ORBIMED ADVISORS LLC | 4,226,843 14.4% | 1,010,637 (+31.42%) | View |